

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

- NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
- NEWS 2 "Ask CAS" for self-help around the clock
- NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
- NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
- NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
- NEWS 6 DEC 14 CA/CAPlus to be enhanced with updated IPC codes
- NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPlus with the IPC reform
- NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
- NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
- NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
- NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
- NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
- NEWS 13 JAN 30 Saved answer limit increased
- NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency added to TULSA
- NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
- NEWS 16 FEB 22 Status of current WO (PCT) information on STN
- NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
- NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
- NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>
- NEWS HOURS STN Operating Hours Plus Help Desk Availability
- NEWS INTER General Internet Information
- NEWS LOGIN Welcome Banner and News Items
- NEWS PHONE Direct Dial and Telecommunication Network Access to STN
- NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 18:00:02 ON 24 FEB 2006

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:00:12 ON 24 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2006 HIGHEST RN 874945-83-2
DICTIONARY FILE UPDATES: 22 FEB 2006 HIGHEST RN 874945-83-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10671376.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:00:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2260 TO ITERATE

88.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 42349 TO 48051
PROJECTED ANSWERS: 30429 TO 35291


L2 50 SEA SSS SAM L1



=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Adenosine, 2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-
(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O,4'-C-
methyleneguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
methylcytidylyl-(3'→5')-2'-O-methyl-, complex with
uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-
uridylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-
uridine (1:1) (9CI)
MF C73 H96 N26 O46 P6 . C67 H82 N26 O49 P6
CM 1

Absolute stereochemistry.



PAGE 1-A







CM 2

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l1 sss full

FULL SEARCH INITIATED 18:00:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 47550 TO ITERATE

100.0% PROCESSED 47550 ITERATIONS

34614 ANSWERS

SEARCH TIME: 00.00.01

L3 34614 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 18:01:03 ON 24 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Feb 2006 VOL 144 ISS 10

FILE LAST UPDATED: 23 Feb 2006 (20060223/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l3 and (radionuclide or auger or electron or emit?)
    37215 L3
    23225 RADIONUCLIDE
    33424 RADIONUCLIDES
    42986 RADIONUCLIDE
        (RADIONUCLIDE OR RADIONUCLIDES)
    41684 AUGER
        115 AUGERS
    41756 AUGER
        (AUGER OR AUGERS)
    1330288 ELECTRON
    256953 ELECTRONS
    1410589 ELECTRON
        (ELECTRON OR ELECTRONS)
    203468 EMIT?
L4    1017 L3 AND (RADIONUCLIDE OR AUGER OR ELECTRON OR EMIT?)
```

```
=> s l4 and (DHT or dihydrotestosterone)
    4844 DHT
        15 DHTS
    4852 DHT
        (DHT OR DHTS)
    9574 DIHYDROTESTOSTERONE
        14 DIHYDROTESTOSTERONES
    9581 DIHYDROTESTOSTERONE
        (DIHYDROTESTOSTERONE OR DIHYDROTESTOSTERONES)
L5    1 L4 AND (DHT OR DIHYDROTESTOSTERONE)
```

=> dis l5 bib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:100738 CAPLUS
TI Novel dosage form comprising modified-release and immediate-release
active ingredients
IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PA India
SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2006024365	A1	20060202	US 2005-134633	20050519
	US 2004096499	A1	20040520	US 2003-630446	20030729
PRAI	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.


IT INDEXING IN PROGRESS

IT 63-39-8, Uridine triphosphate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 63-39-8 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s 14 and (cancer or tumor)
270833 CANCER
39206 CANCERS
281113 CANCER
(CANCER OR CANCERS)
362691 TUMOR
143830 TUMORS
408616 TUMOR
(TUMOR OR TUMORS)
L6 53 L4 AND (CANCER OR TUMOR)

=> s 16 and (scintigraph or imaging)
16 SCINTIGRAPH
20 SCINTIGRAPHS
35 SCINTIGRAPH
(SCINTIGRAPH OR SCINTIGRAPHS)
169831 IMAGING
94 IMAGINGS
169870 IMAGING
(IMAGING OR IMAGINGS)
L7 8 L6 AND (SCINTIGRAPH OR IMAGING)

=> dis 17 1-8 bib abs hitstr

L7 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:77012 CAPLUS
DN 144:169551
TI Antibodies with increased serum half-life and protease resistance prepared
by polynucleotides encoding selector codon, orthogonal RNA synthetase and
orthogonal tRNA
IN Cho, Ho Sung; Daniel, Thomas O.; Wilson, Troy E.; Cujec, Thomas P.; Tian,
Feng; Hays, Anna-Maria; Kimmel, Bruce E.; Ho, Lillian
PA Ambrx, Inc., USA
SO PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006009901	A2	20060126	WO 2005-US21579	20050617
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,				

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM

PRAI US 2004-581334P P 20040618
US 2005-648222P P 20050128
US 2005-654018P P 20050217

AB Novel antigen-binding polypeptides (ABP) or antibody fragments (scFvs) and
conjugates for diagnostic and therapeutic uses thereof are provided.

Thus, modified anti-EGFR periplasmic and cytoplasmic scFv-108 and
anti-HER2 scFv and Fab antibodies were prepared

IT 142451-61-4 721400-99-3 721401-01-0
721401-02-1 721401-03-2 721401-04-3

RL: PRP (Properties)


(unclaimed sequence; antibodies with increased serum half-life and
protease resistance prepared by polynucleotides encoding selector codon,
orthogonal RNA synthetase and orthogonal tRNA)

RN 142451-61-4 CAPLUS


CN Uridine, cytidyl-(3'→5')-cytidyl-(3'→5')-cytidyl-
(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 2-A




RN 721400-99-3 CAPLUS

CN Guanosine, cytidyl-(3'→5')-uridylyl-(3'→5')-adenylyl-
(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 721401-01-0 CAPLUS

CN Uridine, cytidylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





—NH₂



RN 721401-02-1 CAPLUS
 CN Cytidine, cytidylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-
 (3'→5')-uridylyl-(3'→5')- (9CI) (CA INDEX NAME)


Absolute stereochemistry.








RN 721401-03-2 CAPLUS
 CN Adenosine, cytidylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-
 (3'→5')-guanylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 721401-04-3 CAPLUS
 CN Uridine, cytidylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-
 (3'→5')-cytidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PI	WO 2005069994	A2	20050804	WO 2005-US2193	20050124
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

US 2005261170 A1 20051124 US 2005-40114 20050124

PRAI US 2004-538396P P 20040122

AB Because the folate receptor (also called the folate binding protein, FBP) is overexpressed on certain malignant cell types, targeting of the folate receptor has been proposed as a potential mechanism for delivery of drugs and/or radiopharmaceuticals to treat **cancer**. Onconase and/or variants with ribonucleolytic activity, such as rapLRL, present useful therapeutic mols. for preparing folate conjugates and complexes. The conjugates and complexes can be targeted to and internalized by targeted tissues. The conjugates and complexes may be formulated with a pharmaceutically acceptable excipient to form a primary therapeutic agent. The conjugates and complexes may be useful as primary therapeutic agents, which may be administered with addnl. therapeutic or diagnostic agents. Also disclosed are kits that include the conjugates and complexes.

IT 126518-27-2 861895-94-5

RL: PRP (Properties)


(unclaimed sequence; onconase complex conjugated with folate for diagnosis and treatment of **cancer**, infection, cardiovascular disorder and autoimmune disease)



RN 126518-27-2 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A







RN 861895-94-5 CAPLUS
 CN Thymidine, 2'-deoxyadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-
 2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-
 deoxycytidyl-(3'→5')-thymidyl-(3'→5')- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.





L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:755209 CAPLUS
 DN 137:284343
 TI Bisphosphonate conjugates for diagnosis and treatment of bone diseases
 IN Karpeisky, Marat; Padioukova, Nelly; Mikhailov, Sergey; Dixon, H. B. F.;
 Tzeitline, Grigorii
 PA MBC Research, Inc., USA
 SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Pat. Appl.
 2,001,041,689.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002142994	A1	20021003	US 2001-833083	20010410
	US 6896871	B2	20050524		
	US 6214812	B1	20010410	US 1999-283440	19990401
	US 2001041689	A1	20011115	US 2000-731598	20001207
	US 6750340	B2	20040615		
	CA 2443857	AA	20021024	CA 2001-2443857	20010410
	EP 1383510	A1	20040128	EP 2001-926870	20010410

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI	US 1998-80500P	P	19980402
	US 1999-283440	A2	19990401
	US 2000-731598	A2	20001207
	WO 2001-US11827	W	20010410

OS MARPAT 137:284343

AB The present invention is directed to particular bisphosphonate compds., and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone **cancer** and osteoporosis. The bisphosphonate conjugates are capable of releasing an anticancer or antibiotic component upon binding to bone tissue. The conjugates further comprise **imaging** and therapeutic **radionuclides**, e.g., ^{99m}Tc, ¹⁸⁴Rh, or ¹⁸⁶Rh. A vitamin-containing bisphosphonate conjugate useful in treating and preventing disorders of abnormal calcium and phosphate metabolism For example, a vitamin-containing bisphosphonate conjugate 3-(N-pyridoxylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid was obtained as an ammonium salt in a yield of 100 mg (24%) by reaction of 189 mg (1 mmol) 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid and 408 mg (2 mmol) of pyridoxal hydrochloride.

IT 332863-95-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of bisphosphonate conjugates for treatment of soft tissue


surrounding bone and bone-related diseases)

RN 332863-95-3 CAPLUS
CN 5'-Uridylic acid, 5-fluoro-, compd. with N,N-dibutyl-1-butanamine (9CI)
(CA INDEX NAME)

CM 1


CRN 796-66-7
CMF C9 H12 F N2 O9 P

Absolute stereochemistry.



CM 2


CRN 102-82-9
CMF C12 H27 N



IT 374083-83-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of bisphosphonate conjugates for treatment of soft tissue
surrounding bone and bone-related diseases)

RN 374083-83-7 CAPLUS
CN 5'-Uridylic acid, 5-fluoro-, ammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x NH₃

IT 332863-80-6P 332863-84-0P 332863-85-1P
464169-57-1P 464169-58-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(preparation of bisphosphonate conjugates for treatment of soft tissue
surrounding bone and bone-related diseases)

RN 332863-80-6 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with methylenebis[phosphonic acid], ammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x NH₃

RN 332863-84-0 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid], sodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x Na

RN 332863-85-1 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid], lithium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x Li


RN 464169-57-1 CAPLUS
CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464169-58-2 CAPLUS
CN 5'-Uridylic acid, 2'-deoxy-5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:833848 CAPLUS
DN 135:376858
TI Preparation of bisphosphonate conjugates for the treatment of bone cancer or infection
IN Padioukova, Nelly; Mikhailov, Sergey; Dixon, H. B. F.; Tzeitline, Grigorii
PA MBC Research, Inc., Russia
SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. 6,214,812.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001041689	A1	20011115	US 2000-731598	20001207
	US 6750340	B2	20040615		
	US 6214812	B1	20010410	US 1999-283440	19990401
	US 2002142994	A1	20021003	US 2001-833083	20010410
	US 6896871	B2	20050524		
	CA 2443857	AA	20021024	CA 2001-2443857	20010410
	EP 1383510	A1	20040128	EP 2001-926870	20010410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2005026864	A1	20050203	US 2003-742453	20031218
PRAI	US 1998-80500P	P	19980402		
	US 1999-283440	A2	19990401		
	US 2000-731598	A2	20001207		
	WO 2001-US11827	W	20010410		


OS MARPAT 135:376858

AB The present invention is directed to particular bisphosphonate compds.,

and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone **cancer** and osteoporosis. 3-(N-[5'-phospholpyridoxylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid (I) was prepared by the reaction of 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid with pyridoxal-5'-phosphate followed by treatment with NaBH4. Lyophilization of the aqueous solution afforded ammonium salt. The ^{99m}Tc complex of I was prepared and its biodistribution was studied and the results indicated 40-45% of initial radioactivity was accumulated in the bone skeleton.

IT 332863-85-1DP, technetium-99m complexes
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bisphosphonate conjugates for treatment of bone **cancer** or infection)
 RN 332863-85-1 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid], lithium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x Li

IT 796-66-7P 332863-95-3P 374083-83-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bisphosphonate conjugates for treatment of bone **cancer** or infection)
 RN 796-66-7 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 332863-95-3 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, compd. with N,N-dibutyl-1-butanamine (9CI) (CA INDEX NAME)

CM 1

CRN 796-66-7

CMF C9 H12 F N2 O9 P


Absolute stereochemistry.



CM 2

CRN 102-82-9


CMF C12 H27 N



RN 374083-83-7 CAPLUS

CN 5'-Uridylic acid, 5-fluoro-, ammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x NH₃

IT 332863-80-6P 332863-84-0P 332863-85-1P

374083-94-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bisphosphonate conjugates for treatment of bone cancer or infection)

RN 332863-80-6 CAPLUS

CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with methylenebis[phosphonic acid], ammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x NH₃

RN 332863-84-0 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid], sodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x Na

RN 332863-85-1 CAPLUS
 CN 5'-Uridylic acid, 5-fluoro-, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid], lithium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x Li

RN 374083-94-0 CAPLUS
 CN 5'-Uridylic acid, monoanhydride with (1-hydroxyethylidene)bis[phosphonic acid], lithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x Li

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:143395 CAPLUS
DN 128:202466
TI Radiolabeled uridine derivatives, their medical uses, and compositions for preparing them
IN Kamihara, Hajime; Tanaka, Katsutoshi; Yamaguchi, Toshiaki
PA Daiichi Radioisotope Laboratories, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10059990	A2	19980303	JP 1996-231275	19960814
PRAI	JP 1996-231275		19960814		

GI



AB The radiolabeled urine derivs. are prepared by labeling uridine 5'-phosphates I ($n = 1-2$) with metal **radionuclides**. The compns. contain I and reducing agents for metal **radionuclides**. Also claimed are **tumor-imaging agents**, **tumor inhibitors**, and relieving agents against pain caused from bone metastasis. The radiolabeled derivs. accumulates in both primary **tumors** and bone metastasis. A mixture of physiol. saline, UDP, ascorbic acid, and SnCl_2 (pH 2) was treated with a $\text{Na}^{99\text{m}}\text{TcO}_4$ under vigorous stirring to give $^{99\text{m}}\text{Tc}$ -UDP (II). **Imaging of VX-2 tumor** transplanted to a rabbit with II was also shown.


IT **58-98-ODP**, Uridine 5'-(trihydrogen diphosphate), technetium-99-labeled, biological studies **63-39-8DP**, Uridine 5'-(tetrahydrogen triphosphate), technetium-99-labeled

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(preparation of radiolabeled UDP or UTP as **tumor imaging**
agents and **tumor** inhibitors)

RN 58-98-0 CAPLUS

CN Uridine 5'-(trihydrogen diphosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 63-39-8 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 58-98-0, Uridine 5'-(trihydrogen diphosphate), reactions

63-39-8, Uridine 5'-(tetrahydrogen triphosphate)


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of radiolabeled UDP or UTP as **tumor imaging**
agents and **tumor** inhibitors)

RN 58-98-0 CAPLUS

CN Uridine 5'-(trihydrogen diphosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 63-39-8 CAPLUS

CN Uridine 5'-(tetrahydrogen triphosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.





L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:277046 CAPLUS
DN 123:31221
TI **Tumor** targeting with L-enantiomeric oligonucleotide conjugates
of immunoreagents and of chelated **radionuclides**
IN Snow, Robert Allen; Black, Christopher Douglas Valiant
PA Burroughs Wellcome Co., USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 9420523	A1	19940915	WO 1994-US2610	19940310
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2157902	AA	19940915	CA 1994-2157902	19940310
AU 9464025	A1	19940926	AU 1994-64025	19940310
EP 691981	A1	19960117	EP 1994-911542	19940310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08512019	T2	19961217	JP 1994-520313	19940310
PRAI US 1993-33083	A	19930310		
WO 1994-US2610	W	19940310		
AB	The present invention is directed to (1) a non-radioactive targeting immunoreagent that comprises an immunoreactive group, ≥ 1 non-self-associating L-enantiomeric oligonucleotide sequences, and ≥ 1 linking groups and to (2) a radioactive targeting immunoreagent that comprises an L-enantiomeric oligonucleotide sequence that is complementary in sequence to and capable of hybridization with ≥ 1 fragments of a non-self-associating L-enantiomeric oligonucleotide sequence, ≥ 1 chelating agents, ≥ 1 linking groups, and ≥ 1 radionuclides . A pharmaceutical composition comprising ≥ 1 of the above-described immunoreagents and a pharmaceutically acceptable carrier is provided. Methods for treating and imaging disease sites in patients are also disclosed.			
IT	160062-48-6 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nucleotide sequence; tumor targeting with L-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides)			
RN	160062-48-6 CAPLUS			
CN	β -L-Cytidine, 2'-deoxy- β -L-adenylyl-(3'→5')-2'-deoxy- β -L-cytidylyl-(3'→5')- β -L-thymidylyl-(3'→5')-2'-deoxy- β -L-cytidylyl-(3'→5')- β -L-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:612971 CAPLUS

DN 121:212971

TI Sequential targeting of tumor sites with oligonucleotide
conjugates of antibody and complementary radiolabeled oligonucleotides

IN Snow, Robert A.; Groves, Eric S.; Shearman, Clyde W.; Saha, Askis K.; Sen,
Arup; Black, Christopher D. V.

PA Sterling Winthrop Inc., USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 9412216 A1 19940609 WO 1993-US11637 19931130
W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2150477 AA 19940609 CA 1993-2150477 19931130
AU 9457339 A1 19940622 AU 1994-57339 19931130
EP 680335 A1 19951108 EP 1994-903374 19931130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 08503854 T2 19960430 JP 1993-513469 19931130
PRAI US 1992-985699 A 19921130
WO 1993-US11637 W 19931130


AB A non-radioactive targeting immunoreagent is an oligonucleotide that is not self-complementary conjugated to an antibody and a radioactive targeting agent that is an oligonucleotide complementary to part of the sequence conjugated to the antibody and that is radioactively labeled, e.g. by conjugation with a chelating agent that binds a **radionuclide**. The oligonucleotide conjugated to the antibody may be oligomeric or branched to increase binding of the labeled oligonucleotide. These reagents can be used to image disease sites and to treat the disease. The patient is first injected with the unlabeled conjugate and it is allowed to accumulate the **tumor** site and the labeled complementary oligonucleotide is then administered and accumulated at the disease site. The preparation of the oligonucleotides and their conjugation with chelating groups and antibodies was by standard chemical Hybrids showed melting temps of >70°. The method was demonstrated using an antibody to the ING-1 antigen of HT29 cells; using a second oligonucleotide labeled with a fluorescence label it was possible to use the method for fluorescence-activated cell sorting. Pharmacokinetic studies with a radiolabeled oligonucleotide in nude mice showed that the oligonucleotide was rapidly cleared from the blood in the absence of the antibody-bound complementary sequence.


IT 4289-40-1 64816-53-1 70419-20-4
89253-49-6 144676-67-5 158091-71-5
RL: BIOL (Biological study)
(oligonucleotides containing, as linker, for conjugation to antibodies to **tumor** antigens, in preparation oligonucleotide-dependent drug delivery system)

RN 4289-40-1 CAPLUS
CN Cytidine, thymidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-thymidyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 64816-53-1 CAPLUS
 CN Thymidine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70419-20-4 CAPLUS
 CN Cytidine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 89253-49-6 CAPLUS
CN Cytidine, 2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-
deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 144676-67-5 CAPLUS

CN Cytidine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 158091-71-5 CAPLUS
 CN Thymidine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



IT 158091-70-4
 RL: BIOL (Biological study)
 (oligonucleotides containing, conjugation to antibodies to tumor antigens of, in preparation oligonucleotide-dependent drug delivery system)
 RN 158091-70-4 CAPLUS
 CN Cytidine, 2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:400778 CAPLUS
 DN 115:778
 TI Covalently-linked complexes and methods for enhanced cytotoxicity and
 imaging
 IN Anderson, David C.; Morgan, A. Charles; Abrams, Paul G.; Nichols, Everett
 J.; Fritzberg, Alan R.
 PA NeoRx Corp., USA
 SO Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 359347	A2	19900321	EP 1989-250014	19890814
	EP 359347	A3	19900418		
	EP 359347	B1	19921223		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5135736	A	19920804	US 1988-232337	19880815
	US 5169933	A	19921208	US 1989-390241	19890807
	CA 1334513	A1	19950221	CA 1989-608198	19890811
	JP 02124833	A2	19900514	JP 1989-209992	19890814
	AT 83669	E	19930115	AT 1989-250014	19890814
PRAI	US 1988-232337	A	19880815		
	EP 1989-250014	A	19890814		
AB	Covalently-linked complexes (CLCs) for targeting a defined population of cells comprise a targeting protein (e.g. antibody, hormone, enzyme, etc.) a cytotoxic agent (e.g. radionuclide , toxin, drug, etc.) an enhancing moiety capable of enhancing CLC-target cell interaction (e.g. translocating/internalizing moiety, an anchoring peptide, membrane-sol hydrophobic mol., etc.). The CLCs are used to enhance in vivo cytotoxicity and imaging (no data). Translocating peptide, Cys-Gly-Glu-Ala-Ala-Leu-Ala(Glu-Ala-Leu-Ala)4-Glu-Ala-Leu-Glu-Ala-Leu-Ala-NH2, is conjugated via succinimidyl 4(N-maleimidemethyl)cyclohexanecarboxylate (SMCC) to reduced toxin A chain. The conjugate is reacted with iminothiolane to generate further thiol groups which are then bonded to reduced antibody to prepare translocating peptide-ricin A chain-antibody CLC.				
IT	133-89-1D, UDP-glucose, conjugates with cytotoxic agent and targeting protein 528-04-1D, conjugates with cytotoxic agent and targeting protein 2956-16-3D, UDP-galactose, conjugates with cytotoxic agent and targeting protein 3616-06-6D, UDP-xylose, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-8D, UDP-glucosamine, conjugates with cytotoxic agent and targeting protein 17479-04-				

Absolute stereochemistry.




RN 528-04-1 CAPLUS
 CN Uridine 5'-(trihydrogen diphosphate), P'-[2-(acetilamino)-2-deoxy- α -D-glucopyranosyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 2956-16-3 CAPLUS
 CN Uridine 5'-(trihydrogen diphosphate), P'- α -D-galactopyranosyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 3616-06-6 CAPLUS
 CN Uridine 5'-(trihydrogen diphosphate), P'- α -D-xylopyranosyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17479-04-8 CAPLUS
 CN Uridine 5'-(trihydrogen diphosphate), P'-(2-amino-2-deoxy- α -D-glucopyranosyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s Kortylewicz Baranowska Janina/AU
L8 0 KORTYLEWICZ BARANOWSKA JANINA/AU

=> s Kortylewicz-Baranowska Janina/AU
L9 0 KORTYLEWICZ-BARANOWSKA JANINA/AU

=> e Kortylewicz J B/AU
E1 1 KORTYKOVA E N/AU
E2 1 KORTYKOWSKI ANTONI/AU
E3 0 --> KORTYLEWICZ J B/AU
E4 1 KORTYLEWICZ Z/AU
E5 1 KORTYLEWICZ Z P/AU
E6 4 KORTYLEWICZ ZBIGNIEW/AU
E7 12 KORTYLEWICZ ZBIGNIEW P/AU
E8 1 KORTYLEWICZ ZBIGNIEW PAUL/AU
E9 9 KORTYLEWSKA KRISTYNA/AU
E10 2 KORTYLEWSKI BOLESŁAW/AU
E11 2 KORTYLEWSKI M/AU
E12 16 KORTYLEWSKI MARCIN/AU

=> s Kortylewicz Zbigniew/AU
L10 4 KORTYLEWICZ ZBIGNIEW/AU

=> dis l10 1-4 bib abs

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:281656 CAPLUS
DN 142:312180
TI Cancer specific radiolabeled conjugates regulated by the cell cycle for
the treatment and diagnosis of cancer
IN Baranowska-Kortylewicz, Janina; Kortylewicz, Zbigniew
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005069495	A1	20050331	US 2003-671376	20030925
PRAI	US 2003-671376		20030925		
OS	MARPAT 142:312180				

AB Radiolabeled conjugates are disclosed which have a component that is effective to target tumor cells, which cells selectively take up and degrade the conjugate, thereby delivering to the tumor cell nucleus a radioisotope capable of being incorporated into the nuclear material, so as to produce a cytotoxic effect and/or to render the cell detectable by radioimaging.

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:449826 CAPLUS
DN 101:49826
TI Thermal degradation of sodium dodecyl sulfate
AU Patterson, John M.; Kortylewicz, Zbigniew; Smith, Walter T., Jr.
CS Dep. Chem., Univ. Kentucky, Lexington, KY, 40506-0055, USA
SO Journal of Agricultural and Food Chemistry (1984), 32(4), 782-4
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English
AB Pyrolysis at 700° of a tech. grade of SDS which contained an alkyl group distribution of 56.7% dodecyl, 37.5% tetradecyl, and 5.8% hexadecyl resulted in a 65% weight loss and produced 47% of condensable material and 18% of noncondensable gases (largely SO2). The condensable products consisted of the corresponding isomeric alkenes, primary alcs., and ethers. A substantial amount of the mixed ether, dodecyl tetradecyl ether [59012-60-1], was formed along with didodecyl ether [4542-57-8] and ditetradecyl ether [5412-98-6]. In a cytotoxicity screening procedure


using cultured Hamster embryo cells, some of the condensable pyrolyzate components were more toxic than aniline.

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1984:6373 CAPLUS
 DN 100:6373
 TI Acetals and ethers. Part VIII. Organic sulfur compounds. Part I. Synthesis of 2-alkyl-4-(hydroxymethyl)-1,3-dithiolanes and their esters
 AU **Kortylewicz, Zbigniew; Burczyk, Bogdan**
 CS Inst. Org. Polym. Technol., Polytech. Univ., Wroclaw, 50370, Pol.
 SO Polish Journal of Chemistry (1982), 56(4-5-6), 791-7
 CODEN: PJCHDQ; ISSN: 0137-5083
 DT Journal
 LA English
 OS CASREACT 100:6373
 GI



AB Linear alkanals were converted to cyclic acetals I (R = C3-9 n-alkyl); Ac2O and benzoyl chlorides were esterified by I to yield esters II and III (R1 = H, NO2). A mixture of PrCHO, HOCH2CH(SH)CH2SH, and 4-MeC6H4SO3H in C6H6 was refluxed to give I (R = Pr).

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:53725 CAPLUS
 DN 98:53725
 TI Acetals and ethers. Part IX. Organic sulfur compounds. II. Sulfur dioxide as a catalyst in the synthesis of thioacetals from aldehydes or ketones and alkanethiols, alkanedithiols, or hydroxyalkanethiols
 AU Burczyk, Bogdan; **Kortylewicz, Zbigniew**
 CS Inst. Org. Polym. Technol., Tech. Univ., Wroclaw, PL-50-370, Pol.
 SO Synthesis (1982), (10), 831-3
 CODEN: SYNTBF; ISSN: 0039-7881
 DT Journal
 LA English
 OS CASREACT 98:53725
 GI



AB SO2 catalyzes the condensation of RR1CO [R = Me, Et, Pr, (un)substituted Ph; R1 = H, Me] with n-C5H11SH, HSCH2CHR2YH (Y = O, R2 = H; Y = S, R2 = CH2OH) and HS(CH2)3SH to give open-chain and cyclic dithioacetals, RR1C(SC5H11-n)2 (R = Me; R1 = Et, H), I and II, resp.

=> dis hist

FILE 'REGISTRY' ENTERED AT 18:00:12 ON 24 FEB 2006

L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 34614 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:01:03 ON 24 FEB 2006

L4 1017 S L3 AND (RADIONUCLIDE OR AUGER OR ELECTRON OR EMIT?)
L5 1 S L4 AND (DHT OR DIHYDROTESTOSTERONE)
L6 53 S L4 AND (CANCER OR TUMOR)
L7 8 S L6 AND (SCINTIGRAPH OR IMAGING)
L8 0 S KORTYLEWICZ BARANOWSKA JANINA/AU
L9 0 S KORTYLEWICZ-BARANOWSKA JANINA/AU
 E KORTYLEWICZ J B/AU
L10 4 S KORTYLEWICZ ZBIGNIEW/AU